How should a child with early infectious mononucleosis and markedly elevated transaminases be managed?

Management of Elevated Transaminases in Pediatric Infectious Mononucleosis

In a child with early infectious mononucleosis and markedly elevated transaminases, provide supportive care only and monitor liver function closely—do not initiate antiviral or corticosteroid therapy unless life-threatening complications develop.

Understanding the Clinical Context

Elevated liver enzymes are extremely common in infectious mononucleosis (IM), occurring in the majority of pediatric cases. Mildly elevated transaminase levels are a normal feature of acute EBV infection and do not indicate severe liver disease or require specific intervention 1, 2. In one prospective study, mildly elevated transaminases were observed as a characteristic finding during acute presentation, with all laboratory abnormalities returning to normal by 1 month 1.

Monitoring Strategy

Initial Assessment

• Measure ALT, AST, alkaline phosphatase (ALP), total and indirect bilirubin, and lactate dehydrogenase (LDH)
• Check complete blood count with differential
• Assess for hepatomegaly and splenomegaly on physical examination
• Document fever pattern and overall clinical status

Key Thresholds for Concern

Based on pediatric hepatitis B guidelines (which provide the most relevant framework for monitoring transaminase elevations in children), the following approach applies 3:

• If ALT/AST <2× upper limit of normal (ULN): Repeat liver function tests at 2 weeks. If levels are falling, continue monitoring only if symptoms develop
• If ALT/AST 2-5× ULN: Monitor weekly for 2 weeks, then every 2 weeks until normalized
• If ALT/AST ≥5× ULN OR bilirubin rises: This represents significant hepatotoxicity requiring closer monitoring and exclusion of other causes

Follow-Up Monitoring

• Repeat liver function tests every 1-2 weeks during the acute phase
• Most transaminase elevations normalize within 1 month 1
• Continue monitoring until complete normalization

What NOT to Do

Avoid routine corticosteroids: Despite elevated transaminases, corticosteroids are not indicated unless the child develops respiratory compromise or severe pharyngeal edema 4. The evidence does not support routine corticosteroid use for hepatic involvement in IM 5, 4.

Avoid antiviral therapy: Acyclovir and other antivirals are not recommended for routine treatment of infectious mononucleosis, regardless of transaminase levels 4.

Do not restrict acetaminophen unnecessarily: Therapeutic doses of acetaminophen are not contraindicated in children with elevated transaminases from viral hepatitis 6. However, use the lowest effective dose and avoid exceeding recommended daily limits.

Risk Factors for Severe Liver Involvement

Recent pediatric data identified specific predictors of significant liver damage in IM 7, 8:

• Age (younger children may have more pronounced elevations)
• Splenomegaly
• Elevated LDH and ferritin (independent risk factors for liver damage)
• Elevated GGT (gamma-glutamyltransferase)

Children with these features warrant more intensive monitoring but still receive supportive care only.

When to Escalate Care

Consider hospitalization or specialist consultation if:

• ALT/AST ≥5× ULN with rising bilirubin
• Clinical signs of hepatic dysfunction (coagulopathy, altered mental status, jaundice)
• Inability to maintain hydration
• Evidence of splenic rupture (abdominal pain, hemodynamic instability)

Excluding Other Causes

Critical step: Rule out other causes of transaminase elevation, particularly in children with atypical presentations 9:

• Viral hepatitis panel (HAV, HBV, HCV)
• Cytomegalovirus and other herpesvirus testing
• Autoimmune markers if clinically indicated
• Drug/toxin exposure history
• Consider fatty liver disease in obese children

Activity Restrictions

Patients must avoid contact sports and strenuous exercise for 8 weeks from symptom onset or until splenomegaly resolves 10, 5. This is critical regardless of transaminase levels, as splenic rupture (occurring in 0.1-0.5% of cases) is the most feared complication and can be fatal 10.

Expected Clinical Course

• Transaminase elevations typically peak during the first 1-2 weeks of illness
• Most normalize by 1 month 1
• Fatigue may persist for 3 months but does not correlate with transaminase levels
• Persistent elevation beyond 6-8 weeks warrants investigation for chronic EBV infection or alternative diagnoses

Common Pitfalls to Avoid

1. Over-treating with corticosteroids: The presence of elevated LFTs alone does not justify steroid use
2. Premature return to sports: Even with normalizing LFTs, the 8-week activity restriction must be maintained due to splenic rupture risk
3. Unnecessary liver biopsy: Not indicated for transaminase elevations in acute IM
4. Missing alternative diagnoses: Always consider drug-induced liver injury, autoimmune hepatitis, or co-infections

The management priority is preventing splenic rupture through activity restriction and ensuring adequate hydration and nutrition—not treating the transaminase elevation itself, which resolves spontaneously in the vast majority of cases.